Well said, Drano. Once Phase 3 starts, the public
Post# of 72440
1. Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)
http://www.duratatherapeutics.com/news-media/...ission-for
2. The Medicines Company Receives European Commission Approval for Three Hospital Acute Care Products: KENGREXAL™ (cangrelor), ORBACTIV® (oritavancin) and RAPLIXA™ (sealant powder)
http://www.themedicinescompany.com/investors/...acute-care
3. CHMP Says Yes to Two Antibiotics for Skin Infections
http://www.medscape.com/viewarticle/838648